WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 6 fonti

Yes, Revolution Medicine's pancreatic cancer data is that good

When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.

Raccontata dastatnews.combiopharmadive.comendpoints.newsbenzinga.comtheweek.comhindustantimes.com

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
endpoints.newsStai leggendo2 g fa

Yes, Revolution Medicine's pancreatic cancer data is that good

When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.

originale

Timeline cronologica

  1. sabato 30 maggio 2026·statnews.com

    Revolution Medicines starts shipping experimental pancreatic cancer drug

    CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

  2. domenica 31 maggio 2026·biopharmadive.com

    ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

    Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

biopharmadive.com
2 g fa

‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

Leggi questa versione → originale
statnews.com2 g fa

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Revolution Medicines' daraxonrasib, a targeted oral therapy for pancreatic cancer, roughly doubled patient survival versus standard chemotherapy in a Phase trial presented at ASCO 2026 and published simultaneously in the New England Journal of Medicine. For biotech and oncology investors, this is the first meaningful efficacy signal in a notoriously treatment-resistant indication, likely to accelerate M&A interest and pipeline repositioning toward RAS-targeted agents.

Leggi questa versione → originale
benzinga.com1 g fa

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits

Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

Leggi questa versione → originale
theweek.com22 h fa

Pill offers hope in treating deadly pancreatic cancer

Pill users lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy

Leggi questa versione → originale
hindustantimes.com20 h fa

Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

Revolution Medicines' daraxonrasib extends median survival to 13.2 months in pancreatic cancer via a molecular glue approach targeting RAS mutations. For biotech strategists and tech leaders, the molecular glue approach demonstrates advances in structure-based drug design, opening new R&D paradigms in precision medicine.

Leggi questa versione → originale
  • domenica 31 maggio 2026·statnews.com

    Practice-changing results reported for Revolution Medicines pancreatic cancer drug

    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.

  • domenica 31 maggio 2026·endpoints.news

    Yes, Revolution Medicine's pancreatic cancer data is that good

    When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints…

  • lunedì 1 giugno 2026·benzinga.com

    Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits

    Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

  • lunedì 1 giugno 2026·theweek.com

    Pill offers hope in treating deadly pancreatic cancer

    Pill users lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy

  • lunedì 1 giugno 2026·hindustantimes.com

    Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

    While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News